Recombinant factor VIIa analog in the management of hemophilia with inhibitors: Results from a multicenter, randomized, controlled trial of vatreptacog alfa Academic Article uri icon

Overview

MeSH Major

  • Factor VIIa
  • Hemophilia A
  • Recombinant Proteins

abstract

  • This large randomized controlled trial confirmed the well-established efficacy and safety profile of rFVIIa, and showed that vatreptacog alfa had similar or better efficacy than rFVIIa. However, because of the development of anti-drug antibodies, a positive benefit-risk profile is unlikely to be achieved with vatreptacog alfa.

authors

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4238784

Digital Object Identifier (DOI)

  • 10.1111/jth.12634

PubMed ID

  • 24931322

Additional Document Info

start page

  • 1244

end page

  • 53

volume

  • 12

number

  • 8